Evidence map›Paper›PMID 40382614›Full record

ArticleHuman genomics2025

BAX-mediated ammonia-driven cell death: a novel prognostic and therapeutic target in clear cell renal cell carcinoma.

Xi Zhang, Zijie Yu, Lu Yin, Qiang Li, Shaohua He, Heng Li, Jian Li, Lian Sheng, Hongfei Wu, Hongqi Chen and 2 more

Abstract read
In one paragraph

Article in Human genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xi Zhang *Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, People's Republic of China.
Zijie Yu *Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, People's Republic of China.
Lu Yin *Suzhou Industrial Park Xietang Community Health Service Center, Suzhou, 215000, People's Republic of China.
Qiang LiDepartment of Urology, The Affiliated Jiangsu Shengze Hospital of Nanjing Medical University, Suzhou, 215000, People's Republic of China.
Shaohua HeDepartment of Urology, The Affiliated Jiangsu Shengze Hospital of Nanjing Medical University, Suzhou, 215000, People's Republic of China.
Heng LiDepartment of Urology, The Affiliated Jiangsu Shengze Hospital of Nanjing Medical University, Suzhou, 215000, People's Republic of China.
Jian LiDepartment of Urology, The Affiliated Jiangsu Shengze Hospital of Nanjing Medical University, Suzhou, 215000, People's Republic of China.
Lian ShengSuzhou Wujiang District Hospital of Traditional Chinese Medicine (Suzhou Wujiang District Second People's Hospital), Suzhou, 215000, People's Republic of China.
Hongfei WuSuzhou Wujiang District Hospital of Traditional Chinese Medicine (Suzhou Wujiang District Second People's Hospital), Suzhou, 215000, People's Republic of China.
Hongqi ChenDepartment of Urology, The Affiliated Jiangsu Shengze Hospital of Nanjing Medical University, Suzhou, 215000, People's Republic of China. JSSZHCHQ@163.com.
Xiaoxu ZhuYunnan Key Laboratory of Dai and Yi Medicines, Yunnan University of Chinese Medicine, Kunming, Yunnan, 650500, People's Republic of China. zhuxiaoxu19@163.com.
Yang LvDepartment of Urology, The Affiliated Jiangsu Shengze Hospital of Nanjing Medical University, Suzhou, 215000, People's Republic of China. JSSZHLVYANG@163.com.

Funding

2024 Key and Characteristic Discipline of Yunnan Province "First-Class Discipline" Program-Innovative Research Project of Traditional Chinese Medicine ZYXYB202408Joint Special Fund for Traditional Chinese Medicine of the Basic Research Program, Yunnan Provincial Department of Science and Technology 202301AZ070001-131National Administration of Traditional Chinese Medicine High-Level Key Discipline Construction Project "Ethnic Minority Medicine (Dai Medicine)" Zyyzdxk-2023193Scientific Research Fund of Yunnan Provincial Department of Education 2023J0551Suzhou Science and Technology Plan Project SKY2022032
6 · The paper itself

Abstract

backgroundccRCC (clear cell renal cell carcinoma) is characterized by metabolic reprogramming and immunosuppression, leading to poor clinical prognosis. In recent years, ammonia-related cell death has attracted increasing attention as a novel mechanism related to tumor progression, but its role in ccRCC has not been clarified.

methodsIn this study, the Ammonia-related Signature (AS) of ccRCC was constructed by integrating bioinformatics analysis and experimental verification. Multiple independent cohorts including TCGA, PMID 35,440,542 cohort, E-MTAB-1980, and GSE29609 were used to evaluate prognostic accuracy and clinical relevance, and biological functions of key ammonia related genes were explored by cell proliferation, clonal formation, migration, and invasion assays. ScRNA-seq was used to analyze interaction between AS and immune cells in ccRCC.

resultsThe ammonia-related prognostic model demonstrated robust predictive power in multiple datasets. The high AS group of patients with poor prognosis, and the tumor mutation load, immunosuppressive cell infiltration level and immune checkpoint molecular expression were higher. BAX was a key ammonia-related gene closely related to tumor progression, and its knockdown obviously inhibit proliferation, migration and invasion of ccRCC cells. Single-cell analysis confirmed the activation of ammonia-related signaling pathways in the tumor microenvironment, in particular revealing specific interactions between BAX-positive tumor cells and immunosuppressive cell populations.

conclusionThe ammonia-related cell death pathway, especially BAX, can be employed as a potential prognostic marker and therapeutic target for ccRCC, providing new ideas for individualized treatment strategies to overcome immunosuppression and improve clinical prognosis.

Indexed as

Ammoniabcl-2-Associated X ProteinCarcinoma, Renal CellKidney NeoplasmsBiomarkers, TumorCell DeathCell Line, TumorCell MovementCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansMalePrognosisTumor MicroenvironmentAmmoniaBAX protein, humanbcl-2-Associated X ProteinBiomarkers, TumorAmmonia-related cell deathBAXClear cell renal cell carcinomaPrognostic characteristicsSingle-cell RNA sequencing

Identifiers

PMID40382614
PMCPMC12085854

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.